IPO of Organon BioSciences Imminent

van der Zanden, Tim
March 2007
China Chemical Reporter;3/6/2007, Vol. 18 Issue 7, p10
Trade Publication
The article focuses on an announcement made by Akzo Nobel NV regarding its plan of launching an initial public offering (IPO) for the firm Organon BioSciences. A listing of about 20 to 30 percent of Organon BioSciences' shares on Euronext Amsterdam was done by Akzo. According to Hans Wijers, chief executive of Akzo, the IPO will position the company as a coatings and chemicals company.


Related Articles

  • …but it won't rush into purchases. Jagger, Anna // ICIS Chemical Business;6/18/2007, Vol. 2 Issue 71, p44 

    The article reports on the decision of Akzo Nobel not to rush into purchases following its divestment of Organon BioSciences (OBS), according to CEO Hans Wijers. Wijers states that potential acquisition targets would need to fit strategically with the existing portfolio and create value for...

  • Akzo's Chemicals Enter a New Era. Young, Ian // Chemical Week;11/1/2006, Vol. 168 Issue 36, p16 

    The article reports on the decision of Azko Nobel to become a manufacturer of chemicals and coatings after the split-off of its pharmaceuticals business Organon BioSciences (OBS) according to Akzo CEO Hans Wijers. It says that the separation of OBS follows after the completion of a major...

  • Akzo to Float 20%-30% of Pharma Business in Planned IPO; Shareholders Vote Next Month. Young, Ian // Chemical Week;8/23/2006, Vol. 168 Issue 28, p11 

    The article announces the plan of Akzo Nobel to float 20% to 30% of its combined pharmaceutical and veterinary medicines business under a previously announced initial public offering (IPO). Shareholders will vote on plans to split Akzo into two separately quoted companies. Organon BioSciences...

  • Akzo Nobel to IPO Organon. Sinclair, Neil // Chemical Market Reporter;8/21/2006, Vol. 270 Issue 6, p12 

    The article reports that Akzo Nobel, a coatings and health care group, will sell 20 to 30 percent of its Organon Biosciences unit through initial public offering (IPO) in 2007 on the Euronext exchange in Amsterdam, Netherlands. Selling of Organon unit comes after the company disclosed in...

  • Akzo Nobel to Separate into Two Independent Companies.  // China Chemical Reporter;9/26/2006, Vol. 17 Issue 27, p7 

    The article reports on the plan of Akzo Nobel NV in China to separate into two independent companies after the shareholders approved the companies' proposal during an Extraordinary General Meeting. The EGM was cal led to ask shareholders to give their approval to the proposed separation, which...

  • 5-MINUTE NEWS WATCH.  // ICIS Chemical Business Americas;2/19/2007, Vol. 271 Issue 7, p7 

    The article presents news briefs related to the chemical industry as of February 2007. Akzo Nobel plans to conduct an initial public offering (IPO) for 20% to 30% shares of Organon BioSciences on the Euronext exchange. Epichem has been acquired by Sigma Aldrich for $60 million. Merck has decided...

  • AkzoNobel to Expand Presence in India.  // JCT CoatingsTech;Jan2009, Vol. 6 Issue 1, p20 

    The article reports that Amsterdam, the Netherlands-based AkzoNobel has begun construction on a manufacturing plant in India. The facility, which is being built in Hoskote, will produce coil and specialty plastic coatings. According to AkzoNobel Chief Executive Officer Hans Wijers, the company...

  • Akzo Nobel Targeting Coatings Top Spot in China.  // Paint & Coatings Industry;Aug2005, Vol. 21 Issue 8, p20 

    Reports on the goal of Akzo Nobel to become the number-one coatings company in China. Factor to establish the company as a major coatings force in the country; Information on a plant that will be opened by Akzo Nobel in Suzhou site near Shanghai, China; Remarks from Akzo Nobel CEO Hans Wijers...

  • Akzo Nobel and Organon break up. Robinson, Simon // ICIS Chemical Business;8/28/2006, Vol. 1 Issue 32, p11 

    The article reports on the planned separation of Akzo Nobel and Organon into two independent businesses. Akzo Nobel intends to sell its 20-30% stake of its Organon Biosciences through an initial public offering in Amsterdam, Netherlands. Akzo chairman Hans Wijers believes that the presentation...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics